- ISIN
- US26818M1080
- CUSIP
- 26818M108
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Sep 17, 2020
Highlights
- Market Cap
- $2.85B
- Enterprise Value
- $2.12B
- EPS (TTM)
- -$3.29
- Gross Profit (TTM)
- -$521.00K
- EBITDA (TTM)
- -$441.38M
- Year Range
- $8.06 - $25.00
- Target Price
- $37.60
- ROA (TTM)
- -41.83%
- ROE (TTM)
- -52.22%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
DYN Performance Chart
Dyne Therapeutics, Inc. (DYN) is down 11.9% since the beginning of the year. At $17 per share, DYN is trading 31.0% below its 52-week high of $25. Investors who bought $1,000 worth of DYN shares 5 years ago would now be looking at an investment worth $957.
Loading charts...
Returns By Period
Dyne Therapeutics, Inc. (DYN) has returned -11.86% so far this year and 35.75% over the past 12 months.
Dyne Therapeutics, Inc.
- 1D
- -7.46%
- 1M
- -0.86%
- YTD
- -11.86%
- 6M
- -13.76%
- 1Y
- 35.75%
- 3Y*
- 8.68%
- 5Y*
- -0.88%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.13%
- 1M
- 5.25%
- YTD
- 11.16%
- 6M
- 11.43%
- 1Y
- 28.20%
- 3Y*
- 21.12%
- 5Y*
- 12.66%
- 10Y*
- 13.75%
DYN Monthly Returns History
Based on dividend-adjusted daily data since Sep 17, 2020, DYN's average daily return is +0.10%, while the average monthly return is +1.87%. At this rate, an investment would double in approximately 3.1 years.
Historically, 43% of months were positive and 57% were negative. The best month was Oct 2025 with a return of +78.5%, while the worst month was May 2022 at -39.7%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 7 months.
On a daily basis, DYN closed higher 47% of trading days. The best single day was Oct 27, 2025 with a return of +41.2%, while the worst single day was Jan 10, 2025 at -31.2%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -8.54% | -12.69% | 16.07% | -3.20% | 10.14% | -10.81% | -11.86% | ||||||
| 2025 | -39.64% | -4.29% | -23.14% | 12.72% | 1.44% | -20.40% | 3.47% | 36.95% | -6.23% | 78.50% | -3.01% | -10.68% | -16.98% |
| 2024 | 60.90% | 25.70% | 5.54% | -10.85% | 25.96% | 10.70% | 21.59% | 7.41% | -22.07% | -19.65% | 6.06% | -23.03% | 77.14% |
| 2023 | 25.97% | -11.78% | -10.56% | -10.07% | 25.77% | -13.66% | 8.27% | -6.40% | -21.40% | -21.32% | 57.16% | 20.04% | 14.75% |
| 2022 | -37.59% | 15.50% | 12.49% | -17.22% | -39.72% | 42.83% | 52.69% | -6.58% | 29.59% | -10.24% | 2.63% | -0.94% | -2.52% |
| 2021 | -7.95% | -4.45% | -15.92% | 26.72% | -2.90% | 10.10% | -14.12% | -6.31% | -4.08% | -10.65% | -2.07% | -16.33% | -43.38% |
Benchmark Metrics
Dyne Therapeutics, Inc. has an annualized alpha of 0.64%, beta of 1.54, and R2 of 0.11 versus S&P 500 Index. Calculated based on daily prices since September 18, 2020.
- This stock participated in 155.12% of S&P 500 Index downside but only 73.11% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.11 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 0.64%
- Beta
- 1.54
- R²
- 0.11
- Upside Capture
- 73.11%
- Downside Capture
- 155.12%
Return for Risk
Risk / Return Rank
DYN ranks 57 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Dyne Therapeutics, Inc. (DYN) and compare them to S&P 500 Index.
| DYN | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.43 | 2.39 | -1.95 |
Sortino ratioReturn per unit of downside risk | 1.26 | 3.25 | -1.99 |
Omega ratioGain probability vs. loss probability | 1.16 | 1.43 | -0.27 |
Calmar ratioReturn relative to maximum drawdown | 0.80 | 3.11 | -2.31 |
Martin ratioReturn relative to average drawdown | 1.49 | 14.38 | -12.89 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Dyne Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Dyne Therapeutics, Inc. was 85.52%, occurring on Apr 8, 2025. The portfolio has not yet recovered.
The current Dyne Therapeutics, Inc. drawdown is 63.35%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -85.52%Apr 2025 | 7mo 19d | — | 1y 9moAug 2024 - now |
Bear market2022 | -85.12%Jun 2022 | 1y 4mo | 1y 11mo | 3y 4moJan 2021 - May 2024 |
2020 bear market2020 | -29.67%Oct 2020 | 1mo 2d | 14d | 1mo 16dSep 2020 - Nov 2020 |
2020 bear market2020 | -21.47%Nov 2020 | 12d | 1mo 23d | 2mo 5dNov 2020 - Jan 2021 |
2024 correction2024 | -15.18%May 2024 | 7d | 27d | 1mo 4dMay 2024 - Jun 2024 |
Drawdown Indicators
| DYN | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -85.52% | -56.78% | -28.74% |
Max Drawdown (1Y)Largest decline over 1 year | -44.65% | -9.10% | -35.55% |
Max Drawdown (3Y)Largest decline over 3 years | -85.52% | -18.90% | -66.62% |
Max Drawdown (5Y)Largest decline over 5 years | -85.52% | -25.43% | -60.09% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -63.35% | 0.00% | -63.35% |
Average DrawdownAverage peak-to-trough decline | -50.70% | -10.72% | -39.98% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 24.10% | 1.97% | +22.13% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Dyne Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Dyne Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for DYN in comparison with other companies in the Biotechnology industry. Currently, DYN has a P/B value of 3.3. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with DYN
Add Dyne Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with DYN